Hualan Biotech announced on September 23 that the company's shareholding company Hualan Ankang Biology Co., Ltd. applied for marketing license for injectable trastuzumab and obtained a “Notice of Acceptance” issued by the State Drug Administration. Injectable trastuzumab is a monoclonal antibody targeting HER2. The original product name Herceptin is a core first-line drug for the treatment of HER2-positive breast cancer and gastric cancer. Drug indications: HER2 positive early-stage breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.